Paroxetine and naloxone displayed modest efficacy in controlling comorbid depersonalization and dissociative symptoms associated with posttraumatic stress disorder and borderline personality disorder.
Researchers found that significant improvement in symptoms of posttraumatic stress disorder is associated with a lower risk for type 2 diabetes among veterans.
Among individuals with PTSD, those who were victims of terrorist attacks have a higher risk for neoplasms than those who experience other traumatic events.
Palo Alto Health Sciences announced that the FDA has granted clearance to Freespira, a new digital therapeutic for the treatment of PTSD.
